Clinical Trials
240 trialsIsa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
SPiReL
Sunnybrook Health Sciences Centre
DREAMM 14
GlaxoSmithKline
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Takeda
ZUMA-25
Gilead Sciences
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
Entinostat Neuroendocrine (NE) Tumor
Columbia University
EXPAND
Allogene Therapeutics
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
MagnetisMM-9
Pfizer
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
MK-1454-002
Merck Sharp & Dohme LLC
ELARA
Novartis
E7080-G000-231
Merck Sharp & Dohme LLC
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
SELECT
Amgen
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
LuminICE-203
Affimed GmbH
FIGHT-210
Incyte Corporation
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
KarMMa
Celgene
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aprea Therapeutics
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
MacroGenics
PRIMO
SecuraBio
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
TRANSCENDWORLD
Celgene
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
SWOG Cancer Research Network
CAPITAL
AstraZeneca
PETEY
Astellas Pharma Inc
PembroWM
University College, London
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
BeiGene
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Bretuximab
Seoul National University Hospital
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
AstraZeneca
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Palbociclib + Ganitumab In Ewing Sarcoma
Dana-Farber Cancer Institute
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
Eisai Inc.